AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30105460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib with ECF/X
Number of subjects: 28
Study 30105460 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ECF/X
Number of subjects: 28
Study 27230046 — intervention group
Group type: EXPERIMENTAL
Intervention: HMI + PCI (high mechanical index impulses + percutaneous coronary intervention)
Number of subjects: 100
Study 27230046 — intervention group
Group type: EXPERIMENTAL
Intervention: HMI + PCI
Number of subjects: 100
Study 27230046 — intervention group
Group type: EXPERIMENTAL
Intervention: LMI + PCI (low mechanical index imaging + percutaneous coronary intervention)
Number of subjects: 100
Study 27230046 — intervention group
Group type: COMPARATOR
Intervention: PCI only (percutaneous coronary intervention)
Number of subjects: 100
Study 23591152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy snacks (plain yogurt, plain yogurt with honey, strawberry yogurt, skim milk)
Number of subjects: 20
Study 23591152 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk (lowest protein to carbohydrate ratio)
Number of subjects: 20
Study 23591152 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (control group)
Number of subjects: 20
Study 23591152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy snacks (increased protein to carbohydrate ratio)
Number of subjects: 20
Study 23591152 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 20
Study 23022672 — intervention group
Group type: COMPARATOR
Intervention: aripiprazole (3-30 mg/day)
Number of subjects: 58
Study 23022672 — intervention group
Group type: EXPERIMENTAL
Intervention: perospirone (8-48 mg/day)
Number of subjects: 58
Study 20861007 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir (100, 200 mg every 12 h or 8 h for 14 days)
Number of subjects: 50
Study 20861007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18456940 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture treatment (AAT) on active points
Number of subjects: 28
Study 18456940 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment (AAT on sham points)
Number of subjects: 28
Study 18456940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AAT and sham)
Number of subjects: 28
Study 17135738 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate) for 52 weeks
Number of subjects: 634
Study 17135738 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating group (two-compound product and calcipotriol) for 52 weeks
Number of subjects: 634
Study 17135738 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol for 48 weeks after 4 weeks of two-compound product
Number of subjects: 634
Study 14564144 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 14564144 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (including ACE inhibitors, diuretics, digoxin)
Number of subjects: 0
Study 10714842 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 2-3 mg kg(‐1) 24 h(‐1)
Number of subjects: 48
Study 10714842 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 90 mg kg(‐1) 24 h(‐1)
Number of subjects: 48
Study 9186890 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH; N = 30)
Number of subjects: 44
Study 9186890 — intervention group
Group type: COMPARATOR
Intervention: no treatment (N = 14)
Number of subjects: 44
Study 1389194 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg
Number of subjects: 61
Study 3157384 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (Tp-1 Serono)
Number of subjects: 101
Study 3157384 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 101
Study 3157384 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with histiocytosis-X
Number of subjects: 101
Study 31464384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 42
Study 31464384 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 42
Study 29349712 — intervention group
Group type: COMPARATOR
Intervention: RT-HIIT
Number of subjects: 240
Study 29349712 — intervention group
Group type: COMPARATOR
Intervention: AT-HIIT
Number of subjects: 240
Study 28454832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective catheterization strategy (initial CCTA followed by ICA)
Number of subjects: 0
Study 28454832 — intervention group
Group type: COMPARATOR
Intervention: Direct catheterization strategy (direct ICA)
Number of subjects: 0
Study 26340009 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped implants
Number of subjects: 40
Study 26340009 — intervention group
Group type: COMPARATOR
Intervention: Flat implants
Number of subjects: 40
Study 24192331 — intervention group
Group type: COMPARATOR
Intervention: Obese patients (BMI 30.0 to 34.9)
Number of subjects: 5683
Study 24192331 — intervention group
Group type: COMPARATOR
Intervention: Severely obese patients (BMI ≥ 35)
Number of subjects: 5683
Study 21447019 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes
Number of subjects: 20
Study 21447019 — intervention group
Group type: COMPARATOR
Intervention: Probiotic-free artichokes (control)
Number of subjects: 20
Study 18419482 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin monotherapy (400 mg once per day)
Number of subjects: 733
Study 18419482 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus levofloxacin combination therapy
Number of subjects: 733
Study 16843075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10mg b.i.d.
Number of subjects: 24
Study 16843075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20mg b.i.d.
Number of subjects: 24
Study 16843075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14656349 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sublingual immunotherapy (SLIT) combined with inhaled fluticasone (S+F)
Number of subjects: 38
Study 14656349 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo sublingual immunotherapy combined with inhaled fluticasone (placebo S+F)
Number of subjects: 38
Study 14656349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 38
Study 10391417 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-AP 30 mg/day
Number of subjects: 21
Study 10391417 — intervention group
Group type: COMPARATOR
Intervention: 4-AP 6 mg/day (active-treatment control)
Number of subjects: 21
Study 8681509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical naming task
Number of subjects: 0
Study 8681509 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular naming task
Number of subjects: 0
Study 8681509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical decision task
Number of subjects: 0
Study 1641760 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 10 mg/day
Number of subjects: 100
Study 1641760 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care unit support
Number of subjects: 100
Study 6873132 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 50
Study 6873132 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg/day
Number of subjects: 50
Study 31685213 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (PI)
Number of subjects: 2841
Study 31685213 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 2841
Study 29472415 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearGuard HD antimicrobial barrier caps
Number of subjects: 1671
Study 29472415 — intervention group
Group type: COMPARATOR
Intervention: Tego hemodialysis connectors plus Curos disinfecting caps
Number of subjects: 1671
Study 26961929 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus EPA (2 g/d)
Number of subjects: 0
Study 26961929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24505290 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) treatment
Number of subjects: 72
Study 24505290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22062358 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week
Number of subjects: 494
Study 22062358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 20710062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment fasting lipid parameters (total cholesterol, LDL, HDL, apoB, TG)
Number of subjects: 315
Study 17129234 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical eutectic mixture for premature ejaculation (TEMPE)
Number of subjects: 54
Study 17129234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15889624 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative information only
Number of subjects: 230
Study 15889624 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative information plus self-focusing comparison to one's drinking
Number of subjects: 230
Study 15889624 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative information (both contexts)
Number of subjects: 230
Study 15889624 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative information plus self-focus
Number of subjects: 230
Study 15889624 — intervention group
Group type: COMPARATOR
Intervention: Public versus private measurement
Number of subjects: 230
Study 11906518 — intervention group
Group type: EXPERIMENTAL
Intervention: Epileptic seizures (EP)
Number of subjects: 48
Study 11906518 — intervention group
Group type: COMPARATOR
Intervention: Nonepileptic seizures (NES)
Number of subjects: 48
Study 11906518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EP and NES)
Number of subjects: 48
Study 11313161 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg clonazepam
Number of subjects: 26
Study 11313161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9235548 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu-EPO (2000-4000 IU/week for 6 weeks)
Number of subjects: 23
Study 9235548 — intervention group
Group type: COMPARATOR
Intervention: Control group (-EPO)
Number of subjects: 23
Study 8426544 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (MIC)
Number of subjects: 14
Study 8426544 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 14
Study 8426544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity cycling (HIC)
Number of subjects: 14
Study 8426544 — intervention group
Group type: COMPARATOR
Intervention: Normal sedentary activity
Number of subjects: 14
Study 3808791 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A (WHO-recommended oral rehydration solution) containing Na+ 90 mmol/L
Number of subjects: 62
Study 3808791 — intervention group
Group type: COMPARATOR
Intervention: Solution B (Pedialyte RS) containing Na+ 75 mmol/L
Number of subjects: 62
Study 31743094 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group sessions (40-50 min duration)
Number of subjects: 26
Study 29427586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamidol (isobutylamido thiazolyl resorcinol)
Number of subjects: 0
Study 29427586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone
Number of subjects: 0
Study 29427586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 0
Study 29427586 — intervention group
Group type: EXPERIMENTAL
Intervention: Kojic acid
Number of subjects: 0
Study 29427586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone and arbutin
Number of subjects: 0
Study 27577517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy spectral CT with iodixanol (270 mg I/mL)
Number of subjects: 40
Study 27577517 — intervention group
Group type: COMPARATOR
Intervention: Conventional high iodine contrast agent iohexol (350 mg I/mL)
Number of subjects: 40
Study 24788494 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 192
Study 24788494 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (CONV)
Number of subjects: 192
Study 23759172 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Number of subjects: 118
Study 23759172 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline (50 mg/d)
Number of subjects: 118
Study 23759172 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 118
Study 20071998 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training in a balance trainer
Number of subjects: 50
Study 20071998 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 50
Study 20071998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 18191574 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment
Number of subjects: 69
Study 15258611 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.0015%
Number of subjects: 90
Study 15258611 — intervention group
Group type: EXPERIMENTAL
Intervention: brinzolamide 1%
Number of subjects: 90
Study 15258611 — intervention group
Group type: COMPARATOR
Intervention: balanced salt solution
Number of subjects: 90
Study 14512873 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 therapy (SQ IL-10 given daily or thrice weekly)
Number of subjects: 30
Study 10576234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate plus vaginal misoprostol
Number of subjects: 21
Study 10576234 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 21
Study 10576234 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 21
Study 8561109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid hepatitis B vaccination schedule (0, 1, and 2 months)
Number of subjects: 234
Study 8561109 — intervention group
Group type: COMPARATOR
Intervention: Standard hepatitis B vaccination schedule (0, 1, 6 months)
Number of subjects: 234
Study 1984534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine every 2 weeks
Number of subjects: 0
Study 1984534 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine phosphate weekly
Number of subjects: 0
Study 1984534 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine with daily proguanil hydrochloride
Number of subjects: 0
Study 1984534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine dosing regimen
Number of subjects: 0
Study 30688873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral resistance training (back squat)
Number of subjects: 33
Study 30688873 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (step-up)
Number of subjects: 33
Study 30688873 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison)
Number of subjects: 33
Study 30029896 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP (weekly rifapentine plus isoniazid)
Number of subjects: 263
Study 30029896 — intervention group
Group type: COMPARATOR
Intervention: 9H (9-month daily isoniazid)
Number of subjects: 263
Study 26796802 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 100 μg/kg
Number of subjects: 0
Study 26796802 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 6 mg
Number of subjects: 0
Study 26796802 — intervention group
Group type: COMPARATOR
Intervention: rhG‐CSF 5 μg/kg
Number of subjects: 0
Study 24883322 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-PRP injection
Number of subjects: 2
Study 24883322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 22242645 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethyl ester formulation 1 (12 g single dose)
Number of subjects: 0
Study 22242645 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethyl ester formulation 2 (12 g single dose)
Number of subjects: 0
Study 19840120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (non-reimbursed diet drug)
Number of subjects: 0
Study 19840120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (reimbursed diet drug)
Number of subjects: 0
Study 19840120 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular contacts with pharmaceutical sales representatives
Number of subjects: 0
Study 17464747 — intervention group
Group type: EXPERIMENTAL
Intervention: Test patches (two types)
Number of subjects: 29
Study 17464747 — intervention group
Group type: COMPARATOR
Intervention: Negative control patch (0.9% sodium chloride)
Number of subjects: 29
Study 17464747 — intervention group
Group type: COMPARATOR
Intervention: Positive control patch (0.1% sodium lauryl sulphate)
Number of subjects: 29
Study 15893044 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation exercise
Number of subjects: 359
Study 15893044 — intervention group
Group type: COMPARATOR
Intervention: No adaptation exercise (control)
Number of subjects: 359
Study 12141889 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone therapy
Number of subjects: 0
Study 12141889 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (levodopa)
Number of subjects: 0
Study 9659490 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing using a distraction apparatus
Number of subjects: 24
Study 9659490 — intervention group
Group type: COMPARATOR
Intervention: Fracture table nailing
Number of subjects: 24
Study 7652032 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg/kg
Number of subjects: 0
Study 7652032 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 1 mg/kg
Number of subjects: 0
Study 7652032 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 0
Study 7652032 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (various dosages)
Number of subjects: 0
Study 7652032 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of Day (TOD)
Number of subjects: 0
Study 2496668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) + Ftorafur (FT) + Krestin (PSK)
Number of subjects: 3650
Study 2496668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) + PSK
Number of subjects: 3650
Study 2496668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) + Ftorafur (FT)
Number of subjects: 3650
Study 2496668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) + PSK
Number of subjects: 3650
Study 2496668 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + FT + PSK + Picibanil (OK-432)
Number of subjects: 3650
Study 356247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 50 mg b.i.d.
Number of subjects: 0
Study 356247 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg b.i.d.
Number of subjects: 0
Study 31950036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 25
Study 31950036 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 25
Study 27696551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine hydrochloride (35 mg) given i.v.
Number of subjects: 120
Study 27696551 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (i.v. maintaining Ramsay score of 3)
Number of subjects: 120
Study 27696551 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 120
Study 25546476 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic oscillation stimulation (KOS)
Number of subjects: 36
Study 25546476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23582152 — intervention group
Group type: COMPARATOR
Intervention: Patients with IBD
Number of subjects: 0
Study 23582152 — intervention group
Group type: COMPARATOR
Intervention: Patients with IBS
Number of subjects: 0
Study 23582152 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Controls (HCs)
Number of subjects: 0
Study 21820163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (176 μg/d)
Number of subjects: 0
Study 21820163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19438994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% in a new gel formulation
Number of subjects: 123
Study 17472817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 18
Study 17472817 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 80 mg
Number of subjects: 18
Study 17472817 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin and Simvastatin (dose ratios between 1:2 and 1:4)
Number of subjects: 18
Study 15619496 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg IV/oral every 12 hours
Number of subjects: 135
Study 15619496 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g IV every 12 hours
Number of subjects: 135
Study 11391326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray
Number of subjects: 25
Study 11391326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10322832 — intervention group
Group type: EXPERIMENTAL
Intervention: Busui Shengxue Capsule (BSSXC)
Number of subjects: 35
Study 10322832 — intervention group
Group type: EXPERIMENTAL
Intervention: Busui Shengxue Capsule (BSSXC) with IL‐3, IL‐6, IL‐11
Number of subjects: 35
Study 8490109 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine hydrochloride 75 mg after overnight fasting
Number of subjects: 8
Study 8490109 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine hydrochloride 75 mg after a fat- and protein-rich breakfast
Number of subjects: 8
Study 3688070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive management of early labor
Number of subjects: 0
Study 3688070 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 0
Study 30748125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-calorie meal
Number of subjects: 0
Study 30748125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium carbonate (3000 mg)
Number of subjects: 0
Study 30748125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose magnesium hydroxide/aluminum hydroxide (1600 mg each)
Number of subjects: 0